Requests that the FDA revoke its actions to approve the Abbreviate New Drug Application 216616, a generic version of Mifepristone, and modify the associated regimen (including the REMS) until the agency determines that it has complied with the various states’ water quality standards as compelled by the CWA
🏛 Food and Drug Administration (FDA)FDA-2025-P-5434
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.